GlassScriptPhysician profile
Marisol Gomez
NPI 1003496001
$1,076.20
in general payments reported to CMS, 2019-2025
15 companies · $687 in 2025
The $687 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.34 · 2024: $354 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $216.66 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $149.69 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.08 | 2024 | Xifaxan |
| Novo Nordisk INC | $130.33 | 2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $106.09 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $68.72 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.95 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $42.85 | 2025 | Repatha, Otezla |
| Organon LLC | $35.34 | 2022 | |
| Dexcom, INC. | $28.77 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2025 | Rexulti |
| Exact Sciences Corporation | $21.77 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $19.85 | 2025 | Gardasil 9, Capvaxive |
| Phadia US INC. | $19.46 | 2025 | Immunocap |
| Antares Pharma, INC. | $15.27 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.